Screener
Bioventus BVS Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The source filing: Bioventus’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 7:48 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001665988-26-000027
| Line item | Three Months Ended / March 28, 2026 | Three Months Ended / March 29, 2025 |
|---|---|---|
| Net income (loss) | $3,946 | $(3,322) |
| Adjustments to reconcile net income (loss) to net cash from operating activities: | ||
| Depreciation and amortization | 11,205 | 11,865 |
| Provision for credit losses | 230 | 650 |
| Equity-based compensation | 3,264 | 2,414 |
| Deferred income taxes | 135 | 43 |
| Loss on disposals | — | 81 |
| Unrealized loss (gain) on foreign currency fluctuations | 54 | (242) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's accounts receivable, credit loss expense (reversal)?
- Bioventus (BVS) reported accounts receivable, credit loss expense (reversal) of $230K in Q1 2026.
- How has Bioventus's accounts receivable, credit loss expense (reversal) changed year-over-year?
- Bioventus's accounts receivable, credit loss expense (reversal) decreased by 64.6% year-over-year, from $650K to $230K.
- What is the long-term trend for Bioventus's accounts receivable, credit loss expense (reversal)?
- Over 3 years (2021 to 2025), Bioventus's accounts receivable, credit loss expense (reversal) has grown at a 37.3% compound annual growth rate (CAGR), from $485K to $1.26M.
- What does accounts receivable, credit loss expense (reversal) mean?
- Accounts Receivable, Credit Loss Expense (Reversal)
Ask your AI about Bioventus's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude